Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Douglas Middleton Dahl, M.D.

Co-Author

This page shows the publications co-authored by Douglas Dahl and Marc Michaelson.
Connection Strength

0.584
  1. A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524). Int J Radiat Oncol Biol Phys. 2017 04 01; 97(5):995-1001.
    View in: PubMed
    Score: 0.173
  2. Prognostic significance of indeterminate lung nodules in renal cell carcinoma. Urol Oncol. 2014 Apr; 32(3):355-61.
    View in: PubMed
    Score: 0.141
  3. Prognostic significance of indeterminate lung nodules in renal cell carcinoma. J Clin Oncol. 2013 Feb 20; 31(6_suppl):377.
    View in: PubMed
    Score: 0.132
  4. Management of complications of prostate cancer treatment. CA Cancer J Clin. 2008 Jul-Aug; 58(4):196-213.
    View in: PubMed
    Score: 0.095
  5. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 06; 71(6):952-960.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.